Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Eli Lilly's drive to provide as many treatment ... where Zepbound is in a head-to-head contest with the latter's Wegovy (semaglutide) brand. That rivalry looks set to ramp up now that the FDA ...

As the contentious debate over compounded weight loss drugs continues, Eli Lilly is stepping out with an ad campaign ... as Novo’s semaglutide – the active ingredient in Ozempic and Wegovy — in ...

Eli Lilly on Thursday suggested that demand for ... end of the decade as it boosts production of blockbuster obesity drug Wegovy. February 5, 2025 Europe's STOXX 600 closes higher on healthcare ...

Rollout of Wegovy has been affected by production problems, but the Danish company has largely resolved those and said last month it anticipates obesity sales will rise to $3.7 billion in 2025 ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Are you a print subscriber? Activate your account. By Jon Springer - 2 hours 22 min ago By Brian Bonilla - 2 hours 57 min ago By Adrianne Pasquarelli - 5 hours 22 min ago By Javier E. Rodriguez ...